Compare Quest Diagnostics Inc (DGX) vs Ferrari NV (RACE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Ferrari NV — how do they compare? Quest Diagnostics Inc trades at $230.97 (market cap $25.48B), while Ferrari NV trades at $389.91 (market cap $67.35B). The key difference: Ferrari NV is far larger — about 2.6× Quest Diagnostics Inc's market cap, and Quest Diagnostics Inc pays the higher dividend (1.49%). Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and Ferrari NV for 126 Days on average.
| DGX | RACE | |
|---|---|---|
Market Cap | $25.48B | $67.35B |
Volume | 941,866 | 390,618 |
Sector | Health | Consumer Cyclical |
52-Week High | $247.45 | $436.54 |
52-Week Low | $173.49 | $314.63 |
Typical Hold Time | 56 Days | 126 Days |
Enterprise Value | $31.23B | $69.22B |
Dividend Yield | 1.49% | 1.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $230.81, up 1.68% today, with a bullish earnings trend after beating EPS estimates for three consecutive quarters. The stock shows a mixed technical picture with a bearish overall signal but trades near key support at $228. Revenue growth accelerated to $11.04B in 2025, and the company maintains solid profitability with a 9.19% net income margin. Recent news highlights growth in consumer testing and a partnership with Apple Health, though Medicare reimbursement cuts pose a headwind.
The outlook is cautiously optimistic, supported by strong fundamentals and a consensus price target of $250 offering 8% upside. Key opportunities include demand for advanced diagnostics and AI adoption, while risks center on regulatory pressure and rising debt levels. Analyst sentiment is mixed with a slight hold bias, reflecting balanced growth prospects against near-term challenges.
Ferrari (RACE) trades at $388.28, up 0.49% today, with a bearish technical signal but strong fundamentals. The stock has beaten earnings estimates for three consecutive quarters, with Q3 2026 results pending. Revenue grew to $7.15B in 2025, with a net income margin of 22.25% and robust ROE of 45.45%. The company is executing a share buyback program and recently announced a partnership with Rakuten effective January 2027.
The outlook is positive given strong profitability, consistent earnings beats, and analyst consensus favoring a buy rating with a $462.75 price target. Risks include high valuation multiples (P/E 37.19) and exposure to economic cycles affecting luxury demand. Institutional buying and buyback support provide downside cushion, but investors should monitor execution on future growth initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Ferrari NV
Ferrari engineers and manufactures some of the world's most expensive exotic sports cars. The Ferrari brand is synonymous with Formula One racing, exclusivity, Italian design, and state-of-the-art technology. Ferrari also has a captive finance company that provides funding for dealers and clients.
Read more on RACE →
